XENOGRAFT AND CELL LINE CORE

异种移植物和细胞系核心（核心B）将提供最先进的分子表征人类模型，代表项目1 - 3中研究的儿童肉瘤组织型。代表尤文肉瘤的患者来源异种移植物（PDX）（n = 7）。骨肉瘤（n = 10）和横纹肌肉瘤（n = 15）和细胞系（n = 16）可用于研究。核心内品系的真实性和有效性已通过周期性短串联重复序列（STR）分析和分子分析确定。该中心将根据各个项目的需要提供皮下、原位和播散性疾病模型，以及下列服务： 1.维持和表征人异种移植物，并维持通过短串联重复序列（STR）分析鉴定的异种移植物冷冻储备。 2.通过STR分析维护和表征细胞系，用于项目1 - 3。 3.提供用于所有项目的儿科实体瘤异种移植物增殖设施。 4.提供原位和播散性异种移植模型用于二次检测。 5.协调肿瘤移植，并根据需要提供荷瘤小鼠用于药效学和药代动力学研究。 6.协调治疗和组织收集。 7.使用标准化协议进行药物评估研究，并将数据传输到Biostatics Core。 8.提供其他服务（例如，血液和组织采集，用于PK/PD研究）。 9.与生物统计学核心A协商，协助计划和实验设计。 虽然这是一个新的核心，但核心主任拥有超过35年的开发和使用人类肿瘤异种移植模型的经验，自2007年以来已发表了50篇报告使用这些模型评价新药的论文。的

The Xenograft and Cell Line Core (Core B) will provide state of the art molecularly characterized human models representing childhood sarcoma histotypes to be studied in Projects 1-3. Patient derived xenografts (PDX) representing Ewing sarcoma (n=7). Osteosarcoma (n=10) and rhabdomyosarcoma (n=15) and cell lines (n=16) are available for study. Authenticity and validity of lines within the Core have been determined by periodic short tandem repeat (STR) analysis, and molecular profiling. The Core will provide subcutaneous, orthotopic and disseminated disease models as required for individual projects, as well as services listed: 1. Maintain and characterize human xenografts, and maintain frozen stocks of xenografts authenticated by short tandem repeat (STR) analysis. 2. Maintain and characterize cell lines by STR analysis for use in Projects 1-3. 3. To provide a facility for the propagation of xenografts of pediatric solid tumors, for use in all Projects. 4. Provide orthotopic and disseminated xenograft models for secondary testing. 5. Coordinate tumor transplantation and make available tumor-bearing mice for pharmacodynamic and pharmacokinetic studies as required. 6. Coordinate treatment and tissue collection. 7. Undertake drug evaluation studies using standardized protocols, and transfer data to the Biostatics Core. 8. Provide other services (e.g. blood and tissue collection, for PK/PD studies). 9. Assist in planning and experimental design in consultation with the biostatistics Core A. Although this is a new Core, the Core director has over 35 years experience developing and using human tumor xenograft models, and has published 50 papers reporting the evaluation of new agents using these models since 2007. The